62 patents
Utility
Heterodimeric antibodies that bind CD3 and tumor antigens
2 Jan 24
The present invention is directed to novel heterodimeric antibodies.
Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
Filed: 18 Oct 21
Utility
Heterodimeric antibodies that bind CD3 and GPC3
2 Jan 24
Provided herein are novel GPC3 binding domains, and antibodies that include such GPC3 binding domains (e.g., anti-GPC3×anti-CD3).
Alex Nisthal, Nargess Hassanzadeh-Kiabi, Katrina Bykova, Matthew J. Bernett, Rajat Varma
Filed: 10 Mar 22
Utility
Bispecific antibodies that bind to CD38 and CD3
12 Dec 23
The invention provides novel heterodimeric proteins including heterodimeric antibodies.
Matthew Bernett, Seung Chu, Gregory Moore, John Desjarlais
Filed: 30 Oct 20
Utility
Optimized Fc variants
21 Nov 23
The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
Gregory Lazar, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
Filed: 29 Jul 20
Utility
Heterodimeric proteins
14 Nov 23
In one aspect, the present invention provides heterodimeric antibodies comprising a first monomer comprising a first heavy chain constant domain comprising a first variant Fc domain and a first antigen binding domain and a second monomer comprising a second heavy chain constant domain comprising a second variant Fc domain and a second antigen binding domain.
Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
Filed: 2 Nov 20
Utility
Optimized antibody variable regions
8 Aug 23
The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components.
Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
Filed: 4 Jun 21
Utility
IL-12 heterodimeric Fc-fusion proteins
23 May 23
The present invention provides novel IL-12 Fc fusion proteins, methods of making and using the same.
Matthew Bernett, John R. Desjarlais, Rajat Varma, Ke Liu, Nargess Hassanzadeh-Kiabi, Rumana Rashid
Filed: 11 Aug 22
Utility
Heterodimeric proteins
25 Apr 23
The invention provides novel heterodimeric proteins including heterodimeric antibodies.
Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
Filed: 1 Jul 20
Utility
Heterodimeric antibodies that bind CD3 and PSMA
11 Apr 23
The present invention is directed to heterodimeric antibodies that bind CD3 and PSMA.
Gregory Moore, John Desjarlais, Seung Chu
Filed: 7 Dec 16
Utility
Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains
4 Apr 23
The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15Rα Fc fusion protein and an NKG2D antigen binding domain Fc fusion proteins.
Matthew J. Bernett, John R. Desjarlais, Rajat Varma, Gregory Moore, Juan Diaz, Alex Nisthal, Ke Liu, Rumana Rashid, Eric Chang
Filed: 20 Dec 19
Utility
Optimized antibodies that target CD19
4 Apr 23
The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcγR or alters effector function as compared to the parent antibody.
Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik Weiking Pong, John O. Richards, Eugene Alexander Zhukovsky
Filed: 1 Apr 20
Utility
Anti-CD28 compositions
28 Feb 23
Provided herein are novel anti-CD28×anti-B7H3 (also referred to as “αCD28×αB7H3”) heterodimeric bispecific antibodies and methods of using such antibodies for the treatment of cancers.
John R. Desjarlais, Gregory Moore, Michael Hedvat, Juan Diaz, Veronica Gusti Zeng
Filed: 21 Dec 21
Utility
Bispecific heterodimeric fusion proteins containing IL-15-IL-15Ralpha Fc-fusion proteins and immune checkpoint antibody fragments
21 Feb 23
The present invention is directed to novel bispecific heterodimeric Fc fusion proteins comprising an IL-15/IL-15Rα Fc-fusion protein and a PD-1 antibody fragment-Fc fusion protein.
Matthew Bernett, Rumana Rashid, John Desjarlais, Rajat Varma, Christine Bonzon
Filed: 17 Dec 19
Utility
Compositions and methods for treating IgE-mediated disorders
31 Jan 23
The present invention relates to immunoglobulins that bind IgE and FcγRIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE.
John R. Desjarlais, Seung Y. Chu, Holly M. Horton, Matthew J. Bernett
Filed: 5 Feb 20
Utility
Anti-STEAP1 antigen-binding protein
20 Dec 22
The disclosure provides novel antigen-binding proteins that bind STEAP1 and methods of use.
Olivier Nolan-Stevaux, Cong Li, Christopher M. Murawsky, Benjamin M. Alba, Neeraj Jagdish Agrawal, Kevin Graham, Jennitte LeAnn Stevens, Gregory Moore
Filed: 2 Jul 19
Utility
PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
13 Dec 22
The present invention is directed to novel PD-1-targeted IL-15/Rα-Fc fusion proteins comprising an IL-15/IL-15Rα Fc-fusion protein and a PD-1 antigen binding domain.
Matthew Bernett, John Desjarlais, Rumana Rashid, Rajat Varma, Christine Bonzon
Filed: 18 Apr 19
Utility
IL-7-FC-fusion proteins
29 Nov 22
Provided herein are dimeric IL-7-Fc fusion proteins that include Fc domains and one or more IL-7s.
Matthew J. Bernett, John Desjarlais, Suzanne Schubbert, Christine Bonzon, Rajat Varma, Raphael Clynes
Filed: 15 May 20
Utility
TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
22 Nov 22
The present invention is directed to novel targeted heterodimeric fusion proteins comprising an IL-15/IL-15Rα Fc-fusion protein and a TIM-3 antibody fragment-Fc fusion protein.
Matthew J. Bernett, John Desjarlais, Rumana Rashid, Rajat Varma, Christine Bonzon
Filed: 18 Apr 19
Utility
Bispecific checkpoint inhibitor antibodies
8 Nov 22
The present invention is directed to heterodimeric anti-LAG-3×anti-CTLA-4.
Matthew Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon, Alex Nisthal, Umesh S. Muchhal
Filed: 7 Jun 19
Utility
Heterodimeric antibodies that bind ENPP3 and CD3
18 Oct 22
The present invention is directed to antibodies, including novel antigen binding domains and heterodimeric antibodies, that bind Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3).
Rumana Rashid, Umesh S. Muchhal, Gregory Moore, Alex Nisthal, Seung Chu, Sung-Hyung Lee, Yoon Kyung Kim
Filed: 28 Feb 20